teaser
Europe has approved a new type of drug for breast cancer based on a product in the sea sponge.
Halaven (eribulin mesylate) has been licensed as third-line breast cancer therapy in patients with locally advanced or metastatic breast cancer who have failed on two previous courses of chemotherapy.
Prior regimens must have included an anthracycline and a taxane if the patient was eligible to receive these.
The decision follows the same approval by the FDA in November last year.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
It is supported by the EMBRACE trial, a Phase III study that suggest eribulin mesylate boosted overall survival by a median of 2.5 months.
Eisai plans to launch eribulin mesylate across Northern Europe, beginning with the UK.
Eisai 2011
